Corcept Therapeutics Gets FDA Approval for Ovarian Cancer Drug

NEW YORK, March 26 —

Corcept Therapeutics Incorporated received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with shares gaining ground in midday trading.

The approval represents Corcept's first oncology indication and validates the company's selective glucocorticoid receptor antagonist platform beyond its established Cushing's syndrome franchise. Platinum-resistant ovarian cancer affects thousands of women annually who have exhausted standard chemotherapy options, creating a significant commercial opportunity for the biotech company. The combination therapy leverages relacorilant's ability to block cortisol's cancer-promoting effects while enhancing the efficacy of the chemotherapy agent nab-paclitaxel.

Corcept has built its business around Korlym, its first-generation glucocorticoid receptor antagonist for Cushing's syndrome, generating steady revenue growth over recent years. The Lifyorli approval opens a substantially larger addressable market and demonstrates the versatility of the company's drug development platform across multiple therapeutic areas. The FDA decision follows positive Phase 3 trial data showing improved progression-free survival compared to standard chemotherapy alone in this difficult-to-treat patient population.

Investors should monitor the commercial launch timeline and early sales uptake metrics for the Lifyorli combination therapy. Initial prescription trends and oncologist adoption rates will signal whether Corcept can successfully execute its transition from a rare disease specialist to a broader oncology player. The company's ability to penetrate the competitive ovarian cancer treatment landscape will determine whether this approval translates into meaningful revenue growth beyond its core Cushing's syndrome business.

For detailed financial analysis of Corcept Therapeutics, visit /stock/cort to generate a comprehensive Basis Report covering the company's fundamentals and investment outlook.

Basis Report does not hold positions in securities discussed. This is not investment advice.